Mechanical Circulatory Support Therapy in Advanced Heart Failure Book

Preface     v
Acknowledgments     vii
Advanced Heart Failure     1
Epidemiology     1
Management Overview     4
Definition of Mechanical Circulatory Support     34
Evolution of Mechanical Circulatory Support     35
Individual Mechanical Circulatory Support Devices     39
Evaluation     70
Referral Network     70
Initial Encounter     75
Tests     78
General Indications/Contraindications     78
Bridge-to-Transplantation Mechanical Circulatory Support     95
Bridge-to-Recovery Mechanical Circulatory Support     97
Destination Mechanical Circulatory Support     98
Differential Indications by MCSD Type     102
Team Recommendation     103
Patient Decision     107
Management     115
Preoperative Situation     115
Intraoperative Situation     119
Postoperative Situation     120
Long-Term Follow-Up     135
Differential Management by MCSD Type     143
Outcomes     145
Outcome Assessment/Prognostication     145
Bridge-to-Transplantation MechanicalCirculatory Support     155
Bridge-to-Recovery Mechanical Circulatory Support     167
Destination Mechanical Circulatory Support     182
Abiomed     188
Thoratec     189
HeartMate     190
Novacor     193
DeBakey     193
Jarvik 2000     195
Other Mechanical Circulatory Support Devices     196
Differential Outcomes by MCSD Type     198
Complications     200
Multiorgan Failure     200
Right Heart Failure     200
Arrhythmia     204
Infection     205
Bleeding/Hemolysis     221
Renal Dysfunction     228
Respiratory Dysfunction     230
Gastrointestinal Dysfunction     231
Malnutrition     233
Neurological Dysfunction     234
Psychiatric Dysfunction     236
Mechanical Circulatory Support Device Dysfunction     238
Mechanical Circulatory Support Device Failure     242
Differential Complications by MCSD Type     243
Research Strategies     244
Outcomes Research     244
Basic and Translational Research      245
Differential Development by MCSD Type     249
Future Directions     250
Societal Perspectives     252
Role of Governmental Agencies     252
Quality Assurance Considerations     254
Economic Considerations     255
Ethical Considerations     257
Philosophical Considerations     261
Summary     268
References     271
Appendices     297
Evidence-Based Medicine Criteria     297
Contacts (Industry, Expert Societies, Agencies)     302
Infection Protocols     314
Anticoagulation Protocols     317
Columbia University Weaning Protocol     320
Columbia University Evaluation Form     321
Patient/Family Experience Vignettes     325
Glossary     376
Abbreviations     392
Index     395